Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05672251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started2024-01-02
View on ClinicalTrials.gov ↗

Amendment history

2026-07-08
Study Status, Contacts/Locations v11
Recruitment suspended
Reason stopped changed: — → 07/01/2026 DSMC: Pending the response to DSMC conditions (ref. nos. 304808, 302366, 302849, 304156, 304635)
Study sitesdetails revised at 1 of 1 site
2026-07-06
Recruiting→Suspended Study Status, Contacts/Locations v10
Trial statusRecruiting→Suspended
Reason stoppednot stated→07/01/2026 DSMC: Pending the response to DSMC conditions (ref. nos. 304808, 302366, 302849, 304156, 304635)
Study sitesdetails revised at 1 of 1 site
2026-05-07
Study Status v9
Primary completion date2026-04-07→2027-03-23
Completion date2026-04-07→2027-03-23
2025-10-02
Study Status v8
Primary completion date2025-08-24→2026-04-07
Completion date2025-08-24→2026-04-07
2025-05-29
Study Status v7
Primary completion date2025-04-22→2025-08-24
Completion date2025-04-22→2025-08-24
Show 6 earlier versions
2025-02-04
Study Status v6
Primary completion date2024-12-28→2025-04-22
Completion date2024-12-28→2025-04-22
2024-01-29
Study Status v5
Start dateestimated 2023-12-28→confirmed 2024-01-02
2023-11-28
Study Status v4
Start date2023-10-05→2023-12-28
2023-08-24
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2023-08-20
Study Status v2
Start date2023-08-05→2023-10-05
2023-05-26
Study Status v1
Start date2023-05-05→2023-08-05
2023-01-03
Original filing
City of Hope Medical Center
385 trials monitored
See 43 trials at risk
Leukemia
2,553 trials monitored
See 134 trials at risk
Non-Hodgkin Lymphoma
1,512 trials monitored
See 79 trials at risk
DLBCL
648 trials monitored
See 32 trials at risk
and 2 more diseases
This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, loncastuximab, linked to a toxic agent called tesirine. Loncastuximab attaches to anti-CD19 cancer cells in a targeted way and delivers tesirine to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving loncastuximab tesirine with mosunetuzumab may help treat patients with relapsed or refractory diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT05672251
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma +4 more
Enrollment 36 participants
Start Date 2024-01-02
Primary Completion 2027-03-23 (estimated)
Study Completion 2027-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-10